Keywords: Biotie Therapies, Newron Pharma, M&A, CNS drug development

Biotie to buy Newron for 45 million euros, creating a European leader in CNS drug development

Article | 27 September 2011

Print This

In a second acquisition this year, Finland-based biotech company Biotie Therapies (OMX: BTH1V) has entered into an agreement to ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in